The associations between the MCP-1 −2518 A/G polymorphism and ischemic heart disease and ischemic stroke: a meta-analysis of 28 research studies involving 21,524 individuals

Abstract

Epidemiologic studies have been performed to explore the relationship between MCP-1 polymorphism and ischemic heart disease (IHD) and ischemic stroke (IS). But, the results are not consistent. Because of the poor effect of each individual study, we've performed a systematic review and a meta-analysis. A comprehensive search was carried out from PubMed, Embase, Foreign Medical Journal Service (FMJS), China National Knowledge Infrastructure and Wanfang Data. Odds ratios (OR) with 95% confidence interval (CI) were used to evaluate the strength of associations between the MCP-1 A-2518G polymorphism (rs1024611) and IHD and IS susceptibilities. The pooled OR was calculated by the allelic model (G vs A), the additive model (GG vs AA), the dominant model (GG+GA vs AA) and the recessive model (GG vs AA+GA), respectively. The homogeneity among studies was checked using Cochrane Q statistic. The stability of results was checked by one-way sensitivity analysis. The publication bias between studies was examined by Begg's funnel plots and Egger's test. 28 eligible case-control studies met all the criteria and were involved in the present meta-analysis, including a total of 8,901 cases and 12,623 controls. Overall, the MCP-1 A-2518G polymorphism was significantly associated with the IHD susceptibility. The pooled OR was 1.27 (95% CI 1.09-1.48, P = 0.002) in the dominant model, 1.20 (95% CI 1.07-1.35, P = 0.001) in the allelic model, 1.25 (95% CI 1.05-1.50, P = 0.015) in the recessive model and 1.39 (95% CI 1.10-1.75, P = 0.005) in the additive model. At the same time, the MCP-1 A-2518G polymorphism was significantly associated with the IS susceptibility. The pooled OR was 1.72 (95% CI 1.12-2.65, P = 0.013) in the dominant model, 1.39 (95% CI 1.12-1.74, P = 0.003) in the allelic model, 1.59 (95% CI 1.30-1.93, P = 0.000) in the recessive model, and 2.33 (95% CI 1.76-3.08, P = 0.000) in the additive model, respectively. No significant publication bias was found in the present meta-analysis. The results of the present meta-analysis suggest that MCP-1 gene A-2518G polymorphism may be associated with the IHD and IS susceptibilities. But the positive result exists in relatively small sample size subgroup.

The association between three promoter polymorphisms of IL-1 and stroke: A meta-analysis

“…The association between genes and stroke has been confirmed in other meta-analysis, such as MTHFR, MCP-1 Cai et al, 2014). These meta-analysis revealed that genetic variations were significant in stroke; further studies are needed to detect association of genes with stroke.…”

Physical activity initiated by employer induces improvements in a novel set of biomarkers of inflammation: an 8-week follow-up study

“…An abundance of MCP-1 in the vessel wall, along with hyperlipidemia, accelerates atherosclerosis (Lin et al 2014) and may facilitate plaque rupture (Cai et al 2015). In addition, a small increase in MCP-1 is shown to prompt insulin resistance (Sell et al 2006).…”

Polymorphisms of cancer-related genes and risk of multipleprimary malignancies involving colorectal cancer

“…Five of these loci were previously reported to have variable association with the risk of single primary colorectal cancer; rs1061624 of TNFRSF1B, rs1059234 of P21, and rs9344 of CCND1 were found to reduce the risk of colorectal cancer and exert protective effects, while rs28362491 of NFKB1 and rs3212986 of ERCC1 increased the risk of colorectal cancer. Among the other 30 loci, five (rs7566, rs887574, rs13035, rs1799757, and rs5343) are reported for the first time in this study, while 25 were associated with malignant tumor development and the response to chemoradiotherapy (19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33), inflammatory bowel disease (34), autoimmune diseases (35,36), vitiligo (37), insulin resistance (38), coronary heart disease, stroke, and other types of cardiovascular and cerebrovascular disease (39,40).…”